82426-93-5

Usage

Uses

As of now, there is no specific publicly available research that describes the direct applications of 3-hydrazinyl-4-methylpyridazine. However, given its chemical structure and functional groups, it can be inferred that 3-hydrazinyl-4-methylpyridazine may have potential uses in the following areas:
Used in Pharmaceutical Industry:
3-hydrazinyl-4-methylpyridazine is used as a chemical intermediate for the synthesis of various drugs and pharmaceuticals, due to its ability to participate in chemical reactions as a nucleophile or reducing agent.
Used in Chemical Synthesis:
3-hydrazinyl-4-methylpyridazine is used as a building block in the synthesis of other organic compounds, leveraging the reactivity of its hydrazinyl and methyl groups in organic chemistry.

Upstream product

• 68206-04-2 3-chloro-4-methylpyridazine 
• 105537-47-1 ethyl 2-methyl-4,4-diethoxybutanoate 
• 105537-87-9 4-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 33471-40-8 4-methylpyridazin-3(2H)-one 
• 61892-47-5 α-methyl-γ-hydroxybutyrolactone 

Downstream Products

• 90568-15-3 3-amino-4-methylpyridazine 

Relevant academic research and scientific papers

4- [HETEROCYCLYL-METHYL] -8-FLUORO-QUINOLIN-2-ONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS

Novel compounds of formulae (II, III) and pharmaceutical compositions have been found to inhibit inducible NOS synthase wherein: R4, R5, R6 and R7 are independently selected from the group consisting of hydrogen, lower alkyl, and halogen; and, R8 has the structure whrein X1, X2, X3, X4, X5, X6, R9, R13, R14 and n are as described herein.

Synthesis and Structure-Activity Relationships of Series of Aminopyridazine Derivatives of γ-Aminobutyric Acid Acting as Selective GABA-A Antagonists

We have recently shown that an aryloaminopyridazine derivarive of GABA, SR 95103 , is a selective and competitive GABA-A receptor antagonist.In order to further explore the structural requirements for GABA receptor affinity, we synthesized a series of 38 compounds by attaching various pyridazinic structures to GABA or GABA-like side chains.Most of the compounds displaced GABA from rat brain membranes.All the active compounds antagonized the GABA-elicited enhancement of diazepam binding, strongly suggesting that all these compounds are GABA-A receptor antagonists.None of the compounds that displaced GABA from rat brain membranes interacted with other GABA recognition sites (GABA-B receptor, GABA uptake binding site, glutamate decarboxylase, GABA-transaminase).They did not interact with the Cl- ionophore associated with the GABA-A receptor and did not interact with the benzodiazepine, strychnine, and glutamate binding sites.Thus these compounds appear to be specific GABA-A receptor antagonists.In terms of structure-activity, it can be concluded that a GABA moiety bearing a positive charge is necessary for optimal GABA-A receptor recognition.Additional binding sites are tolerated only if they are part of a charge-delocalized amidinic or guanidinic system.If this delocalization is achieved by linking a butyric acid moiety to the N(2) nitrogen of a 3-aminopyridazine, GABA-antagonistic character is produced.The highest potency (ca.250 times bicuculline) was observed when an aromatic ? system, bearing electron-donating substituents, was present on the 6-position of the pyridazine ring.